https://www.greenmedinfo.com/blog/mushroom-power-five-therapeutic-properties-medicinal-mushrooms1?

Mushroom Power: Five Therapeutic Properties of Medicinal Mushrooms

© 4/22/21] GreenMedInfo LLC. This work is reproduced and distributed with the permission of GreenMedInfo LLC. Want to learn more from GreenMedInfo? Sign up for the newsletter here:  //www.greenmedinfo.com/greenmed/newsletter.

Mushrooms have recently gained popularity in culinary circles, but their far-reaching therapeutic properties should get your attention for a longer and healthier life

Although mushrooms have been part of the healer’s toolbox since ancient times, the medicinal power of mushrooms is gaining momentum in evidence-based journals.

Medicinal mushrooms come in a wide variety and shapes such as white button, reishi, maitake, shiitake, oyster, cordyceps, cauliflower, tiger tail and lion’s mane, and most have health benefits that range from fighting cancer and boosting your immunity and memory to preventing diseases like diabetes and arthritis.

Five Therapeutic Properties of Mushrooms

1. Anticancer

Reishi (in Japanese) or lingzhi (in Chinese) mushrooms are well known in Asia for their anticancer properties. In a meta-analysis by scientists of 23 trials involving 4,246 cancer patients, reishi mushrooms enhanced longevity and quality of life in cancer patients.[i]

Therapy with white button mushrooms impacted prostate-specific antigen (PSA) levels and inhibited prostate cancer by decreasing immunosuppressive factors.[ii]

Polysaccharides from Cordyceps cicadae mushrooms inhibited the growth of cancer cells and induced cancer cell deaths showing its effectiveness as a low cost and safe treatment for cervical cancer.[iii]

A peptide from the shiitake mushroom showed promising results in growth arrest, cell death and cleaning out damaged cells in a breast cancer in vitro study.[iv] In both in vitro and in vivo studies, results showed that mice with induced testicular cancer treated with the Cordyceps sinensis mushroom had significantly smaller and fewer tumors than the control group.[v]

Cordyceps cicadae mushroom treatment prevented testicular damage and tumors caused by the chemotherapy drug cisplatin via inhibition of oxidative stress and inflammation in rats.[vi]

In a lung cancer-induced study of mice, treatment with reishi mushrooms inhibited cell viability and mobility of lung cancer cells in vitro.[vii] In a cell study of reishi mushroom extract, the treatment offered high antitumor and liver protection with low toxicity on human liver cancer cells.[viii]

2. Immunomodulatory

In a meta-analysis of 20 animal disease studies, grifola frondosa, or maitake mushroom, polysaccharide showed strong immune function by enhancing T cells, natural killer cells and macrophages in mice and increasing the secretion of two important immune factors, TNF-α and INF-γ.[ix]

In a clinical study of 105 cancer patients undergoing chemotherapy or radiation treatments, a combination of reishi mushroom extract and geraniums improved immunity and fought the cancer and secondary infections that could have compromised treatment and health.[x]

In a study of 18 patients diagnosed with low and intermediate myelodysplastic syndrome, which can lead to leukemia if not managed well, maitake mushroom extract treatment of three milligrams (mg) twice a day for 12 weeks increased immunity, positively affecting neutrophil, monocyte and free radical production.[xi]

In a clinical study of asymptomatic children from 3 to 5 years old, treatment with beta glucans from reishi mushrooms showed increased immune system cells in the peripheral blood — signaling a strong defense against childhood infections.[xii]

Reviewing in vivo and in vitro studies on mice and human cell lines using lion’s mane (Hericium erinaceus) and tiger tail (Trametes versicolor) mushrooms, treatments showed immunomodulatory, anticancer, anti-inflammatory and neuroregenerative effects.[xiii]

3. Antioxidant

Polysaccharide beta glucan extracted from reishi mushroom was shown to be a powerful antioxidant in 37 high risk and 34 stable angina patients; those who were treated with 750 mg per day for three months had significantly decreased oxidative radicals and improved progression of atherosclerosis.[xiv]

In a study of 42 healthy subjects, another intervention with beta glucan from reishi mushrooms of 225 mg per day for three months demonstrated its antioxidative effects — enhanced total antioxidant capacity and enzyme activities as well as reduced mild fatty liver condition to normal by suppressing oxidative stress were observed.[xv]

4. Anti-inflammatory 

Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract. Treatment with a triterpene compound from reishi mushrooms showed that the inflammatory cytokines were significantly inhibited in a study of children with Crohn’s disease.[xvi]

Sixty patients with moderate persistent asthma were studied and those who took the cordyceps sinensis mushroom capsule for two months had reduced airway inflammation caused by their chronic asthma.[xvii]Cordycepin from medicinal mushrooms showed strong effects on many anti-inflammatory diseases.[xviii]

In a study of 32 patients with active rheumatoid arthritis, supplementation of medicinal mushroom and Chinese herbs — reishi (4 grams) and San Miao San (2.4 grams) daily — lowered arthritic pain for patients.[xix] The data in a mice study support a model where white button mushrooms regulate immunity in vitro and protect the colon from inflammation-induced injuries in vivo.[xx]

The brain is susceptible to inflammation as well. In an Alzheimer’s disease model of rats, treatment with medicinal mushroom extracts delayed disease progression, improved learning and memory functions and stopped neural cell deaths and brain atrophy.[xxi]

Chaga mushrooms administered to mice successfully protected against Alzheimer’s disease by modulating oxidative stress, Nrf2 signaling and mitochondrial cell deaths while improving memory and cognition.[xxii]Cordycepin from the Cordyceps sinensis mushroom alleviated Parkinson’s disease motor disorder symptoms by lowering oxidative stress and inflammation in vivo and in vitro.[xxiii]

Lion’s mane mushrooms were supplemented for 12 weeks and were effective in preventing dementia and cognitive decline.[xxiv] Lion’s mane supplementation for four weeks in a study of 30 females also reduced depression and anxiety.[xxv]

5. Antidiabetic

Dyslipidemia, high blood cholesterol and triglycerides is often a harbinger of future diabetes. In a rat model, white button mushrooms and a probiotic were found to lower dyslipidemia and decrease oxidative stress.[xxvi] In a study of 89 diabetic patients, oyster mushroom consumption significantly reduced blood glucose, blood pressure, triglycerides and cholesterol without ill effects on the liver or kidneys.[xxvii]

Polyphenols from Phellinus igniarius, or willow bracket, mushroom extract were used in vitro and in vivo studies of induced Type 2 diabetes mice and showed improved glucose tolerance, reduced hyperglycemia and normalized insulin levels.[xxviii]

Diabetic nephropathy, kidney disease caused by Type 2 diabetes, was studied in vitro with disease-induced rats and treatment with Cordyceps cicadae resulted in improved insulin resistance and glucose tolerance, suppressed inflammation and balanced gut microbiome thus stopping the diabetes-related progression of renal disease and tumors.[xxix]

In an animal study, maitake mushroom prevented the progression of kidney fibrosis in diabetic nephropathy rats, significantly decreased fasting blood glucose levels, reduced inflammatory cytokines and lowered renal fibrosis indexes indicating its effectiveness in the treatment or prevention of nephropathy.[xxx]

In their meta-analysis of 623 articles and 33 randomized controlled experiments using cauliflower mushroom extract (S. Crispa), researchers found statistically significant differences in diabetic symptoms including decreased serum insulin levels and wound rates and an increase in nutrient intake content.[xxxi]

Mushrooms and Their Medicinal Powers

Medicinal mushrooms are widely researched and used as treatment in the prevention and progression of many diseases from cancer and asthma to diabetes and dementia. Mushrooms protect you due to their anti-inflammatory, antitumor, antidiabetic, immune boosting and antioxidant activities. To learn more, see GreenMedInfo.com’s database on mushrooms.


References

[i] Zhong L, Yan P, Lam WC, Yao L, Bian Z. Coriolus Versicolor and Ganoderma Lucidum Related Natural Products as an Adjunct Therapy for Cancers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2019 Jul 3;10:703. doi: 10.3389/fphar.2019.00703. PMID: 31333449; PMCID: PMC6616310.

[ii] Przemyslaw Twardowski, Noriko Kanaya, Paul Frankel, Timothy Synold, Christopher Ruel, Sumanta K Pal, Maribel Junqueira, Manisha Prajapati, Tina Moore, Pamela Tryon, Shiuan Chen. A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responses. Cancer. 2015 Sep 1 ;121(17):2942-50. Epub 2015 May 18. PMID: 25989179

[iii] Jiao Xu, Zhi-Cheng Tan, Zhong-Yuan Shen, Xing-Jia Shen, Shun-Ming Tang. Cordyceps cicadae polysaccharides inhibit Human cervical cancer Hela cells proliferation via Apoptosis and Cell Cycle Arrest. Food Chem Toxicol. 2021 Jan 6:111971. Epub 2021 Jan 6. PMID: 33421460

[iv] Syed Riaz Ud Din, Mintao Zhong, Muhammad Azhar Nisar, Muhammad Zubair Saleem, Akbar Hussain, Kavish H Khinsar, Shahid Alam, Gohar Ayub, Sadia Kanwal, Xingyun Li, Wei Zhang, Xiaoli Wang, Anhong Ning, Jing Cao, Min Huang. Latcripin-7A, derivative of Lentinula edodes C, reduces migration and induces apoptosis, autophagy, and cell cycle arrest at Gphase in breast cancer cells. Appl Microbiol Biotechnol. 2020 Dec ;104(23):10165-10179. Epub 2020 Oct 12. PMID: 33044599

[v] Ming-Min Chang, Siou-Ying Hong, Shang-Hsun Yang, Chia-Ching Wu, Chia-Yih Wang, Bu-Miin Huang. Anti-Cancer Effect of Cordycepin on FGF9-Induced Testicular Tumorigenesis. Int J Mol Sci. 2020 Nov 6 ;21(21). Epub 2020 Nov 6. PMID: 33172093

[vi] Ling Wang, Yigang He, Yudi Li, Chengbin Pei, Opeyemi Joshua Olatunji, Jian Tang, Ademola C Famurewa, Hongyan Wang, Bei Yan. Protective Effects of Nucleosides-Rich Extract from Cordyceps cicadae against Cisplatin Induced Testicular Damage. Chem Biodivers. 2020 Nov ;17(11):e2000671. Epub 2020 Nov 3. PMID: 33007148

[vii] Wei-Hung Hsu, Wei-Lun Qiu, Shu-Ming Tsao, Ai-Jung Tseng, Mei-Kuang Lu, Wei-Jyun Hua, Hsin-Chung Cheng, Hsien-Yeh Hsu, Tung-Yi Lin. Effects of WSG, a polysaccharide from Ganoderma lucidum, on suppressing cell growth and mobility of lung cancer. Int J Biol Macromol. 2020 Oct 1. Epub 2020 Oct 1. PMID: 33011264

[viii] Liping Zhu, Min Wu, Peng Li, Yanfei Zhou, Jinyi Zhong, Zhiqiang Zhang, Ye Li, Weixi Yao, Jianhua Xu. High-Pressure Supercritical COExtracts ofFruiting Body and Their Anti-hepatoma Effect Associated With the Ras/Raf/MEK/ERK Signaling Pathway. Front Pharmacol. 2020 ;11:602702. Epub 2020 Dec 14. PMID: 33381043

[ix] Zhang T, Zhao F, Wu KN, Jia Y, Liao XL, Yang FW, Zhang JH, Ma B. Meta-analysis on effect of Grifola frondosa polysaccharide in regulating in vivo immunoregulatory function on animal disease models. Zhongguo Zhong Yao Za Zhi. 2019 Dec;44(23):5174-5183. Chinese. doi: 10.19540/j.cnki.cjcmm.20190823.401. PMID: 32237355.

[x] Zhuang SR, Chen SL, Tsai JH, Huang CC, Wu TC, Liu WS, Tseng HC, Lee HS, Huang MC, Shane GT, Yang CH, Shen YC, Yan YY, Wang CK. Effect of citronellol and the Chinese medical herb complex on cellular immunity of cancer patients receiving chemotherapy/radiotherapy. Phytother Res. 2009 Jun;23(6):785-90. doi: 10.1002/ptr.2623. PMID: 19145638.

[xi] Wesa KM, Cunningham-Rundles S, Klimek VM, Vertosick E, Coleton MI, Yeung KS, Lin H, Nimer S, Cassileth BR. Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study. Cancer Immunol Immunother. 2015 Feb;64(2):237-47. doi: 10.1007/s00262-014-1628-6. Epub 2014 Oct 29. PMID: 25351719; PMCID: PMC4317517

[xii] Sandra Lorena Duque Henao, Sergio A Urrego, Andrea M Cano, Edwin A Higuita. Randomized Clinical Trial for the Evaluation of Immune Modulation by Yogurt Enriched withβ-Glucans from Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes), in Children from Medellin, Colombia. Int J Med Mushrooms. 2018 ;20(8):705-716. PMID: 30317947

[xiii] Mateusz Winder, Weronika Bulska-Będkowska, Jerzy Chudek. The use of Hericium erinaceus and Trametes versicolor extracts in supportive treatment in oncology. Acta Pharm. 2021 Mar 1 ;71(1):1-16. PMID: 32697746

[xiv] Djanggan Sargowo, Nadia Ovianti, Eliana Susilowati, Nizamuddin Ubaidillah, Adriyawan Widya Nugraha, Vitriyaturrida, Kartika Siwi Proboretno, Mirza Failasufi, Fadhli Ramadhan, Hesti Wulandari, Yoga Waranugraha, Dinarsari Hayuning Putri. The role of polysaccharide peptide of Ganoderma lucidum as a potent antioxidant against atherosclerosis in high risk and stable angina patients. Indian Heart J. 2018 Sep – Oct;70(5):608-614. Epub 2017 Dec 14. PMID: 30392496

[xv] Hui-Fang Chiu, Hui-Yu Fu, Yan-Ying Lu, Yi-Chun Han, You-Cheng Shen, Kamesh Venkatakrishnan, Oksana Golovinskaia, Chin-Kun Wang. Triterpenoids and polysaccharide peptides-enriched Ganoderma lucidum: a randomized, double-blind placebo-controlled crossover study of its antioxidation and hepatoprotective efficacy in healthy volunteers. Pharm Biol. 2017 Dec ;55(1):1041-1046. PMID: 28183232

[xvi] Changda Liu, David Dunkin, Joanne Lai, Ying Song, Clare Ceballos, Keith Benkov, Xiu-Min Li. Anti-inflammatory Effects of Ganoderma lucidum Triterpenoid in Human Crohn’s Disease Associated with Downregulation of NF-κB Signaling. Inflamm Bowel Dis. 2015 May 19. Epub 2015 May 19. PMID: 25993687

[xvii] Ning-qun Wang, Liang-duo Jiang, Xiao-mei Zhang, Zong-xin Li. Effect of dongchong xiacao capsule on airway inflammation of asthmatic patients. J Hypertens. 2005 Sep;23(9):1699-706. PMID: 17972591

[xviii] Tan L, Song X, Ren Y, Wang M, Guo C, Guo D, Gu Y, Li Y, Cao Z, Deng Y. Anti-inflammatory effects of cordycepin: A review. Phytother Res. 2020 Oct 8. doi: 10.1002/ptr.6890. Epub ahead of print. PMID: 33090621.

[xix] Edmund K Li, Lai-Shan Tam, Chun Kwok Wong, Wai Ching Li, Christopher W K Lam, Sissi Wachtel-Galor, Iris F Benzie, Yi Xi Bao, Ping Chung Leung, Brian Tomlinson. Safety and efficacy of Ganoderma lucidum (lingzhi) and San Miao San supplementation in patients with rheumatoid arthritis: a double-blind, randomized, placebo-controlled pilot trial. J Pediatr Gastroenterol Nutr. 2010 Feb;50(2):208-11. PMID: 17907228

[xx] Sanhong Yu, Veronika Weaver, Keith Martin, Margherita T Cantorna. The effects of whole mushrooms during inflammation. BMC Immunol. 2009;10:12. Epub 2009 Feb 20. PMID: 19232107

[xxi] Guoxiao Lai, Yinrui Guo, Diling Chen, Xiaocui Tang, Ou Shuai, Tianqiao Yong, Dongdong Wang, Chun Xiao, Gailian Zhou, Yizhen Xie, Burton B Yang, Qingping Wu. Alcohol Extracts FromDelay the Progress of Alzheimer’s Disease by Regulating DNA Methylation in Rodents. Front Pharmacol. 2019 ;10:272. Epub 2019 Mar 26. PMID: 30971923

[xxii] Yanqiu Han, Shanji Nan, Jia Fan, Qiuhui Chen, Yizhi Zhang. Inonotus obliquus polysaccharides protect against Alzheimer’s disease by regulating Nrf2 signaling and exerting antioxidative and antiapoptotic effects. Int J Biol Macromol. 2019 Mar 13 ;131:769-778. Epub 2019 Mar 13. PMID: 30878614

[xxiii] Chunyan Cheng, Xiaoying Zhu. Cordycepin mitigates MPTP-induced Parkinson’s disease through inhibiting TLR/NF-κB signaling pathway. Life Sci. 2019 Feb 18. Epub 2019 Feb 18. PMID: 30790609

[xxiv] Yuusuke Saitsu, Akemi Nishide, Kenji Kikushima, Kuniyoshi Shimizu, Koichiro Ohnuki. Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomed Res. 2019 ;40(4):125-131. PMID: 31413233

[xxv] Nagano M, Shimizu K, Kondo R, Hayashi C, Sato D, Kitagawa K, Ohnuki K. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res. 2010 Aug;31(4):231-7. doi: 10.2220/biomedres.31.231. PMID: 20834180.

[xxvi] Farhan Asad, Haseeb Anwar, Hadi M Yassine, Muhammad Irfan Ullah, Aziz Rahman, Zahid Kamran, Muhammad Umar Sohail. White Button Mushroom, Agaricus bisporus (Agaricomycetes), and a Probiotics Mixture Supplementation Correct Dyslipidemia without Influencing the Colon Microbiome Profile in Hypercholesterolemic Rats. Int J Med Mushrooms. 2020 ;22(3):235-244. PMID: 32479018

K Khatun, H Mahtab, P A Khanam, M A Sayeed, K A Khan. Oyster mushroom reduced blood glucose and cholesterol in diabetic subjects. Mymensingh Med J. 2007 Jan;16(1):94-9. PMID: 17344789

[xxvii] K Khatun, H Mahtab, P A Khanam, M A Sayeed, K A Khan. Oyster mushroom reduced blood glucose and cholesterol in diabetic subjects. Mymensingh Med J. 2007 Jan;16(1):94-9. PMID: 17344789

[xxviii] Sijian Zheng, Shihao Deng, Yun Huang, Mi Huang, Ping Zhao, Xinhua Ma, Yanzhang Wen, Qiang Wang, Xinzhou Yang. Anti-diabetic activity of a polyphenol-rich extract from Phellinus igniarius in KK-Ay mice with spontaneous type 2 diabetes mellitus. Food Funct. 2018 Jan 24 ;9(1):614-623. PMID: 29271444

[xxix] Junling Yang, Huibin Dong, Ya Wang, Yun Jiang, Wenna Zhang, Yongming Lu, Yan Chen, Lei Chen. Cordyceps cicadae polysaccharides ameliorated renal interstitial fibrosis in diabetic nephropathy rats by repressing inflammation and modulating gut microbiota dysbiosis. Int J Biol Macromol. 2020 Nov 15 ;163:442-456. Epub 2020 Jun 24. PMID: 32592781

[xxx] Tao Jiang, Liang Wang, Angjie Ma, Yi Wu, Qiwen Wu, Qiulin Wu, Jianwei Lu, Tian Zhong. The hypoglycemic and renal protective effects of Grifola frondosa polysaccharides in early diabetic nephropathy. J Food Biochem. 2020 Oct 11:e13515. Epub 2020 Oct 11. PMID: 33043487

[xxxi] Thi Nhu Ngoc L, Oh YK, Lee YJ, Lee YC. Effects of Sparassis crispa in Medical Therapeutics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int J Mol Sci. 2018 May 16;19(5):1487. doi: 10.3390/ijms19051487. PMID: 29772715; PMCID: PMC5983641.

https://www.theblaze.com/op-ed/horowitz-120-doctors-ask-jama-to-retract-misleading-colombian-study-downplaying-efficacy-of-ivermectin

Horowitz: 120 doctors ask JAMA to retract misleading Colombian study downplaying efficacy of ivermectin

OP-ED

Why is there such an agenda to discredit cheap, repurposed drugs?

We knew this would happen. The health establishment didn’t use fabricated data from a study authored by a science fiction writer and porn star (later retracted), as they did with hydroxychloroquine, but it was almost as bad.

No, they didn’t find any harm from ivermectin, but after every study showing the amazing efficacy of ivermectin against SARS-CoV-2 at every stage of the disease, the media breathlessly promoted a Colombian study supposedly showing no statistically meaningful benefit among those COVID-19 patients who were treated with it.

Last month, a group of Colombian researchers published a study in the Journal of the American Medical Association (JAMA) concluding that, contrary to the findings of every other study, ivermectin showed no signs of bettering outcomes in COVID-19 patients in Cali, Colombia.

“Among adults with mild COVID-19, a 5-day course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms,” concluded the authors. “The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.”

(See link for article)

 
**Comment**
 
Once again the spin-doctors are hard at work discrediting a powerful, cheap drug that works on COVID.
 
The article points out:

After ignoring dozens of other studies on ivermectin for months, the New York Times got hold of this study the day it was published and penned an article titled, “Popular Drug Does Not Alleviate Mild Covid-19 Symptoms, Study Finds.”

Horowitz points out the study was flawed from the beginning and its results do not support the authors’ conclusions.
Thankfully, honest doctors are screaming bloody-murder and have written a letter  to JAMA:

The study’s flaws span subject population, design, execution and controls. The small sample size (n = 400) had a median age of 37 and a BMI of 26, making them extremely low risk for COVID-19 hard endpoints. Faced with this low-relevance study group, the study authors improperly changed primary endpoint midway, moving the main endpoint to full symptom resolution by day 21. This self-reported subjective endpoint, obtained through telephone survey, is not credible for avoiding nondifferential nullward bias of the results.

The authors incorrectly administered ivermectin on an empty stomach, reducing drug bioavailability in lung tissue, the critical drug target, by a factor of roughly 2.5. Additionally, ivermectin is readily available over-the-counter in Colombia, where sales have been ubiquitous (1.6 doses per COVID-19 case) in Cali during the study period.[2] Lack of serum testing in the study prevented identification of subjects who may have used the drug at intervals longer than the study lookback.

Thus, you literally had a placebo control group where they didn’t ensure they were not taking ivermectin! On top of this, the department of health in the state of Valle del Cauca – where this study took place – began distributing ivermectin to COVID patients right when the study period began.

Also, just from June to July of last year when the study period began, over-the-counter sales of ivermectin in the Cali region quintupled.

The doctors protesting this study originally sent this letter to JAMA to be published, but after JAMA declined, the authors posted it as an open letter on their own landing page.

Horowitz also points out they violated participant consent rules by not telling the study participants they were receiving ivermectin.

The Front Line COVID-19 Critical Care Alliance (FLCCC), which is the lead group in the United States promoting ivermectin as the staple of COVID early therapeutic treatment, wrote a paper calling into question the protocols of the study, noting that a labeling error substituted 38 ivermectin doses as part of the placebo group.

They also accuse the authors of a conflict of interest for receiving grants from “Sanofi Pasteur, a vaccine manufacturer; Janssen, a J&J vaccine partner; and GlaxoSmithKline, Merck, and Gilead, which manufacture COVID-19 drugs.”

Oops.  

Meanwhile, Gilead is raking in the dough through its sale of Remdesivir (over $3K per treatment) despite ZERO evidence of efficacy.  It’s still being used as the only major treatment, while the FDA is now going after anyone who mentions things like vitamin C, zinc, and other natural remedies.

And never, ever forget the atrocious, fraudulent, government funded study on HCQ which was finally retracted, and the fact the AAPS sued the FDA for “irrational” interference of Access to life-saving Hydroxychloroquine.”

All research needs independent scrutiny.  I’m eternally grateful for the doctors and researchers who do this work on their own dime.  Without this exposure, the world would blindly accept fraudulent studies.  It’s also up to us to educate others on this diabolical take-over of science and the need to question ALL OF IT.
We are living in 1984.
 
 

**UPDATE Feb. 2023**

COVID was a catalyst for showing the ongoing disagreement about the isolation of viruses like never before.  Please know that similarly to the issue of persistence with Lyme/MSIDS, there is controversy about the exact definition of virus isolation.  To better educate yourself on this topic please see the many articles that follow:

Pro-virus:

https://redpilluniversity.org/2021/02/14/chinas-chief-epidemiologist-admits-covid-19-was-never-proven-to-exist/

China’s Chief Epidemiologist Admits COVID-19 was Never Proven to Exist

Andrew Kaufman, MD, interviewed by Del Bigtree, delivers an excellent short course on the risks of Covid tests and vaccines. The Interview is preceded by a short clip from an NBC report on 2021 January 23 in which China’s Chief epidemiologist, Dr. Wu Zunyou, says:

“They didn’t isolate the virus, and that is the problem.”

Dr. Kaufman explains why that means there is no proof that a Covid-19 virus even exists and, instead, could be merely a variant of the common flu. This interview includes a summary of the debate between advocates of the germ theory and the terrain theory of disease. Be prepared for a deep dive into concepts and dogma that seldom are discussed but which are critical to disease control. 2020-07-20 – Source: Andrew Kaufman

You can view this video from several sources. Cached versions are adjusted for optimum quality, if needed, and they provide access if original sources fail.

Some recent talks have been given by knowledgable practitioners on what illness this actually is (a bioweapon utilizing spike proteins that damage the lungs & organs).  Dr. Merrit’s talk “Biowarfare & weaponization of medicine amid COVID” can also be found here since Youtube censored it.

I write about our personal experiences with this illness here. (Scroll to comment section.  All treatments should be discussed with your practitioner.)  Similarly with Lyme/MSIDS, good doctors giving the truth on effective treatments are being heavily censored and persecuted – but these treatments exist, work well, are safe, and are inexpensive.

IMG-20210506-WA0003

https://danielcameronmd.com/lyme-disease-cause-chronic-illnesses/

LYME DISEASE AS A REVERSIBLE CAUSE OF CHRONIC ILLNESS FOR SOME PATIENTS

lyme-disease-cause-chronic-illness

As the number of individuals with chronic illnesses continues to rise, clinicians and patients are looking for reversible causes to chronic symptoms that are often debilitating to patients. Reversible causes have included dementia, [1] coma, [2] complex arrhythmia, [3] and autoimmune encephalitis. [4]

Studies indicated that Lyme disease can lead to chronic disease including Lyme encephalopathy, [5] Lyme neuropathy, [6] chronic neurologic Lyme disease, [6] and Neuropsychiatric Lyme disease. [7]

Could Lyme disease be a reversible cause of other chronic illnesses in some patients? Having a high index of suspicion will prevent missing the diagnosis.

Following are dozens of published papers, described in an Inside Lyme Blog series, which features cases in which Lyme disease was a reversible cause of other chronic medical conditions. [8]

Brain Diseases and Neurological Disorders

80-year-old with Lyme encephalopathy instead of dementia
Chronic post-concussion syndrome symptoms due to Lyme disease
POTS patients with brain fog have neurocognitive deficits
When it looks like a brain tumor, but it is Lyme disease
Untreated Lyme disease triggers a stroke in 9-year-old boy
Lyme podcast: man with Lyme disease and stroke
Child with Lyme disease presenting as pseudotumor cerebri
Chronic inflammatory demyelinating polyneuropathy (CIDP) case resolved with antibiotics
Lyme meningitis, manifesting as parkinsonism, is fully reversed with ceftriaxone
Seizures and altered mental status after a tick bite
Dementia and normal pressure Hydrocephalus
Cognitive issues following a stroke due to Lyme disease
Stroke as a manifestation of Lyme disease
Lyme disease causes ‘false brain tumor’ in young child

Cardiac Disease

Broad range of presentations for Lyme carditis cases
Lyme carditis presenting as atrial fibrillation treated successfully
First report of Lyme disease causing mitral valve endocarditis
Lyme endocarditis in 68-year-old avid outdoorsman
Another cardiac manifestation of Lyme myocarditis
When Lyme disease mimics a heart attack
Physician-turned-patient becomes Lyme advocate – required a heart transplant

Autonomic Disorders

POTS: an autonomic disorder in Lyme disease patients
Subacute transverse myelitis caused by Borrelia infection
Femoral neuropathy as a neurologic symptom of Lyme disease
Autonomic dysfunction, small fiber neuropathy and Lyme disease
Acute transverse myelitis in a 25-year-old man with Lyme disease

Sleep Disorders

Lyme disease is associated with various sleep disorders

Psychiatric Illnesses

16-year-old boy with Lyme disease presenting as depression
Don’ t confuse somatic symptoms with depression in early Lyme disease
Oppositional behavior in children with Lyme disease
Can Lyme disease trigger obsessive compulsive symptoms?
Depression common in Lyme disease patients
Suicidal behaviors in patients with Lyme and associated diseases
7-year-old girl with Lyme disease presenting as attention deficit disorder
Treatment options for an anxious, suicidal patient with a history of Lyme disease

Movement Disorders

Subacute Parkinsonism as a complication of Lyme disease

Auditory Problems

Study finds hearing loss and tinnitus common in patients with tick-borne diseases
Lyme disease patient with permanent tinnitus and hearing loss

Autoimmune/Immune System Disorders

Lyme podcast: Sjögren’s syndrome secondary to Lyme disease
Can Lyme disease trigger an autoimmune disease? – Adult-onset Still’s disease (AOSD)
Lyme disease mimics autoimmune disorder in elderly woman – dermatomyositis
Could Lyme disease be another infection associated with the onset of Guillain-Barre syndrome?
PANDAS and Lyme disease in a 7-year-old child

Dermatological Conditions

6-year-old girl with a rare cutaneous presentation of Lyme disease – areolar lymphocytomainvolving her breast
Lyme disease mimics cellulitis skin infection
Lyme disease misdiagnosed as shingles in 62-year-old man

Sensory Impairments

What is that smell?

Eye or Ocular Disorders

Study looks at uveitis due to Lyme disease
69-year-old man with Lyme disease and double vision
Visual changes due to Lyme disease
Growing list of eye problems in Lyme disease
Lyme disease causes vision loss in 46-year-old woman

Inflammatory Disease

Can Lyme disease trigger sarcoidosis?

Joint Infections

Lyme disease mimics prosthetic joint infection following knee replacement

Gastrointestinal Illnesses

Neurologic Lyme disease presenting as abdominal pain in 71-year-old patient
Lyme disease manifests as abdominal pain in young child

 Kidney Disease

Doctors recognize Lyme disease in a patient with kidney disease
Kidney failure and disseminated rashes associated with Lyme disease


Conclusion: Substantial variability exists in the presenting features and clinical course of patients with Lyme disease. A diagnosis depends upon a thorough clinical evaluation, physical and neurologic examinations, along with laboratory testing. An accurate diagnosis and proper treatment can improve the outcome of patients with reversible causes of chronic symptoms.

References:
  1. Bello VME, Schultz RR. Prevalence of treatable and reversible dementias: A study in a dementia outpatient clinic. Dement Neuropsychol. Jan-Mar 2011;5(1):44-47. doi:10.1590/S1980-57642011DN05010008
  2. Edlow JA, Rabinstein A, Traub SJ, Wijdicks EF. Diagnosis of reversible causes of coma. Lancet. Dec 6 2014;384(9959):2064-76. doi:10.1016/S0140-6736(13)62184-4
  3. Pozzolini A, Rio T, Padeletti M, De Ponti R, Leonelli FM, Bagliani G. Complex Arrhythmias Due to Reversible Causes. Card Electrophysiol Clin. Jun 2019;11(2):375-390. doi:10.1016/j.ccep.2019.03.002
  4. Pandit AK, Ihtisham K, Garg A, Gulati S, Padma MV, Tripathi M. Autoimmune encephalitis: A potentially reversible cause of status epilepticus, epilepsy, and cognitive decline. Ann Indian Acad Neurol. Oct 2013;16(4):577-84. doi:10.4103/0972-2327.120476
  5. Logigian EL, Kaplan RF, Steere AC. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. J Infect Dis. Aug 1999;180(2):377-83. doi:10.1086/314860
  6. Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med. Nov 22 1990;323(21):1438-44. doi:10.1056/NEJM199011223232102
  7. Fallon BA, Nields JA. Lyme disease: a neuropsychiatric illness. Am J Psychiatry. Nov 1994;151(11):1571-83. doi:10.1176/ajp.151.11.1571
  8. Inside Lyme Science blog. https://danielcameronmd.com/daniel-cameron-md-lyme-blog/ Last accessed 12/19/20.

https://www.lymedisease.org/neuropsych-lyme-jane-marke/

Managing mental health and neuropsychiatric symptoms of Lyme disease